{"id":"W2239738725","doi":"10.1016/s1473-3099(15)00466-1","title":"Alternatives to antibiotics—a pipeline portfolio review","year":2016,"lang":"en","type":"review","venue":"The Lancet Infectious Diseases","topic":"Bacteriophages and microbial interactions","field":"Environmental Science","cited_by":844,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pan-Provincial Vaccine Enterprise; University of British Columbia","funders":"Biotechnology and Biological Sciences Research Council; Wellcome Trust","keywords":"Antibiotics; Portfolio; Investment (military); Intensive care medicine; Business; Medicine; Risk analysis (engineering); Biology; Political science; Finance; Microbiology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02986273729200503,"score_gpt":0.3458707339456072,"score_spread":0.3160079966536022,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}